GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genmab AS (NAS:GMAB) » Definitions » 5-Year Yield-on-Cost %

GMAB (Genmab AS) 5-Year Yield-on-Cost % : 0.00 (As of Mar. 26, 2025)


View and export this data going back to 2019. Start your Free Trial

What is Genmab AS 5-Year Yield-on-Cost %?

Genmab AS's yield on cost for the quarter that ended in Dec. 2024 was 0.00.


The historical rank and industry rank for Genmab AS's 5-Year Yield-on-Cost % or its related term are showing as below:



GMAB's 5-Year Yield-on-Cost % is not ranked *
in the Biotechnology industry.
Industry Median: 1.59
* Ranked among companies with meaningful 5-Year Yield-on-Cost % only.

Competitive Comparison of Genmab AS's 5-Year Yield-on-Cost %

For the Biotechnology subindustry, Genmab AS's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Genmab AS's 5-Year Yield-on-Cost % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Genmab AS's 5-Year Yield-on-Cost % distribution charts can be found below:

* The bar in red indicates where Genmab AS's 5-Year Yield-on-Cost % falls into.



Genmab AS 5-Year Yield-on-Cost % Calculation

Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.

Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.

Therefore, Yield-on-Cost of Genmab AS is calculated as

Yield-on-Cost=Dividend Yield %*(1+Dividend Growth Rate)^5

Genmab AS  (NAS:GMAB) 5-Year Yield-on-Cost % Explanation

Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.


Genmab AS 5-Year Yield-on-Cost % Related Terms

Thank you for viewing the detailed overview of Genmab AS's 5-Year Yield-on-Cost % provided by GuruFocus.com. Please click on the following links to see related term pages.


Genmab AS Business Description

Address
Carl Jacobsens Vej 30, Valby, DNK, 2500
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.

Genmab AS Headlines